A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group (Q74341821)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 September 2000

Language	Label	Description	Also known as
English	A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group	scientific article published on 01 September 2000

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

randomized experiment

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Douglas P. Kiel

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

author name string

C H Chesnut

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

S Silverman

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

K Andriano

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

H Genant

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

A Gimona

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

S Harris

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

M LeBoff

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

M Maricic

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

P Miller

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

C Moniz

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

M Peacock

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

P Richardson

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

N Watts

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

D Baylink

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

publication date

1 September 2000

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

American Journal of Medicine

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

109

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

267-276

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

randomized experiment

0 references

Ultrastructural effects of calcitonin on osteoclasts in tissue culture

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

The effects of parathyroid hormone, colchicine, and calcitonin on the ultrastructure and the activity of osteoclasts in organ culture

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Nasal calcitonin for treatment of established osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Effect of salcatonin given intranasally on early postmenopausal bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Long-term treatment of established osteoporosis with intranasal calcitonin.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Long-term calcitonin therapy in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Effects of calcitonin on bone quality and osteoblastic function

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Effect of salmon calcitonin on femoral bone quality in adult ovariectomized ewes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

The role of skeletal calcium deficiency in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Dual X-ray absorptiometry quality control: comparison of visual examination and process-control charts

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Comparative calibration without a gold standard

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

An evaluation of antibodies and clinical resistance to salmon calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

In vitro detection of neutralizing antibodies after treatment of Paget's disease of bone with nasal salmon calcitonin.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

The crippling consequences of fractures and their impact on quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Exploiting and bypassing the bone remodeling cycle to optimize the treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

A double blind study of intranasal calcitonin for established postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900490-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0002-9343(00)00490-3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996576%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q74341821&oldid=1759492471"